Marietta Investment Partners LLC Reduces Position in Eli Lilly and Company $LLY

Marietta Investment Partners LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 15.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,993 shares of the company’s stock after selling 709 shares during the period. Marietta Investment Partners LLC’s holdings in Eli Lilly and Company were worth $4,291,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Norges Bank purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $12,976,634,000. Capital Research Global Investors boosted its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. Amundi boosted its holdings in shares of Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after acquiring an additional 964,675 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of Eli Lilly and Company by 22.3% in the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock valued at $5,517,059,000 after acquiring an additional 937,204 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its pipeline with a $1.9 billion partnership with Ascidian Therapeutics focused on kidney disease treatments, reinforcing management’s strategy of using obesity cash flow to fund acquisitions and diversify beyond GLP-1 drugs. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Lilly reported encouraging clinical updates for its obesity and immunology pipeline, including progress in the TRIUMPH-1 retatrutide study and a pediatric ulcerative colitis trial for mirikizumab, both of which support longer-term growth expectations. Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race Lilly’s Pediatric Ulcerative Colitis Trial Marks Key Step for Mirikizumab Growth
• Positive Sentiment: Coverage news also remained favorable, with CVS Caremark and other major pharmacy benefit managers broadening access to Lilly’s obesity portfolio, which should improve prescription volume for Zepbound and Foundayo. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,330.00 in a report on Thursday, May 21st. Barclays upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,081.34 on Thursday. The company’s fifty day moving average price is $965.78 and its 200 day moving average price is $1,011.48. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,149.10. The company has a market capitalization of $1.02 trillion, a PE ratio of 38.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.